CC 1
Alternative Names: Bispecific PSMAxCD3 antibody; CC-1Latest Information Update: 24 Jul 2024
At a glance
- Originator Bicony Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 19 Jul 2024 Bicony Therapeutics completes the enrolment from its Phase-I clinical trials in Prostate cancer (Hormone refractory) in Germany (Parenteral)
- 31 May 2024 Efficacy and adverse event data from the phase I trial in Prostrate cancer at the 60th Annual Meeting of the American Society of Clinical Oncology 2024 (ASCO-2024)